Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

X T L Biopharmaceuticals Ltd (NASDAQ:XTLB)

1.85
Delayed Data
As of 11:20am ET
 +0.1499 / +8.82%
Today’s Change
1.48
Today|||52-Week Range
5.00
-6.57%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$20.2M

Company Description

XTL Biopharmaceuticals Ltd engages in the acquisition and development of proprietary products and late-stage pharmaceutical products for the treatment of unmet clinical needs. It has three product candidates in clinical development: the hCDR1 peptide for the treatment of Systemic Lupus Erythematosus; Recombinant Erythropoitin for the prolongation of multiple myeloma advanced-stage patients' survival and improvement of their quality of life; and SAM-101, a therapy for psychotic diseases, with focus on schizophrenia. The company was founded on March 9, 1993 and is headquartered in Raanana, Israel.

Contact Information

XTL Biopharmaceuticals Ltd.
5 HaCharoshet Street
Raanana Hamerkaz 43656
P:(729) 955-7080
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Joshua LevineChief Executive Officer
David KestenbaumChief Financial Officer
Moshe MittelmanMedical Director
Daniel H. ShapiraInternal Auditor
Navon ShalomController